9 completed, 1 recruiting. 10 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 9, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow RTV: new trials by email Literature Review of RTV trials Research Report on RTV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STARLITE for Unresectable High-Grade Gliomas Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine - High Grade Glioma | Phase 1 | Recruiting | University of Miami | 24 | 2025-04-15 | 2026-06-25 |
| GLS4/RTV and TAF Drug-drug Interaction GLS4, RTV, TAF - Chronic Hepatitis B | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 28 | 2021-01-10 | 2022-05-26 |
| A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects GLS4, RTV, ETV - Chronic Hepatitis B | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 56 | 2018-06-26 | 2019-10-09 |
| Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China Ravidasvir, Danoprevir, Ritonavir - Healthy | Phase 1 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 18 | 2016-07-15 | 2018-06-29 |
| Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China Danoprevir, Ritonavir, Placebo - Healthy | Phase 1 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 18 | 2015-10-01 | 2017-01-13 |
| Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study atazanavir 300mg boosted with ritonavir 50 mg - HIV Infection | Phase 1 | Completed | Ottawa Hospital Research Institute | 12 | 2014-01-01 | 2015-09-22 |
| Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) IDX719, Simeprevir, TMC647055 - Hepatitis C, Chronic | Phase 1 | Completed | Merck Sharp & Dohme LLC | 34 | 2013-05-01 | 2016-01-26 |
| GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir GSK1349572, Atazanavir 300 mg, Atazanavir 400 mg - Healthy Volunteer | Phase 1 | Completed | GlaxoSmithKline | 24 | 2009-04-01 | 2009-06-22 |
| Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children Atazanavir, Darunavir, Efavirenz - HIV Infections | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 75 | 2006-02-01 | 2021-11-09 |
| Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects TPV low, Placebo, Moxifloxacin - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 81 | 2005-12-01 | 2014-09-25 |
HIV Infections (2) · Hepatitis B, Chronic (2) · Glioma (1) · Hepatitis C (1) · Hepatitis C, Chronic (1)
Ascletis Pharmaceuticals Co., Ltd. (2) · Sunshine Lake Pharma Co., Ltd. (2) · Boehringer Ingelheim (1) · GlaxoSmithKline (1) · Merck Sharp & Dohme LLC (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Ottawa Hospital Research Institute (1) · University of Miami (1)
United States (3) · China (2) · Canada (1) · Puerto Rico (1)
Huoling Tang, PhD (2) · Ashish Shah, MD (1) · Jennifer King, PharmD (1) · Macarena De La Fuente, MD (1) · Ram Yogev, MD (1) · William Cameron, MD, FRCPC (1) · Yanhua Ding, Doctor (1)